Photo of Mark S. Huberman,   M.D.

Mark S. Huberman, M.D.

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-9236
Fax: (617) 975-5665


mhuberma@caregroup.harvard.edu

Mark S. Huberman, M.D.

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Staff, Hematology/Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research interests focus on Phase I-III clinical trials in solid tumors especially lung, esophagus, colorectal, and breast cancers. Current projects include multi-modality treatment of locally advanced lung and esophageal cancer, evaluation of matrix metallo proteinase inhibitors in lung cancer, and anticipate project evaluating EGF receptor antagonist in lung cancer Phase I Study of an outpatient regimen of recombinant human.

Publications

Powered by Harvard Catalyst
  • Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovksy Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer 2015. PubMed
  • Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer 2015. PubMed
  • Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 2015. PubMed
  • Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014; 84:39-44. PubMed
  • Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013; 5:216ra177. PubMed
  • Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol 2013; 8:1438-44. PubMed
  • Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer 2013; 82:31-7. PubMed
  • Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013; 19:3068-77. PubMed
  • Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2012; 8:45-51. PubMed
  • Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol 2010; 5:1855-8. PubMed
  • Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol 2010; 5:1048-53. PubMed
  • Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4:1389-96. PubMed
  • Ye C, Masterman JR, Huberman MS, Gangadharan SP, McDonald DC, Kent MS, DeCamp MM. Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience. Chest 2009; 136:710-5. PubMed
  • Wong ET,Huberman M,Lu XQ,Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008; 26:5649-50. PubMed
  • Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008; 14:7060-7. PubMed
  • Heist RS,Fidias P,Huberman M,Ardman B,Sequist LV,Temel JS,Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:1153-8. PubMed
  • Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007; 4:1669-79; discussion 1680. PubMed
  • Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 2007; 58:95-103. PubMed
  • Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2006; 60:295-303. PubMed
  • Lam P, Berman S, Thurer R, Ashiku S, Decamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II Trial of Sequential Chemotherapy Followed by Chemoradiation, Surgery, and Postoperative Chemotherapy for the Treatment of Stage IIIA/IIIB Non-Small-Cell Lung Cancer. Clin Lung Cancer 2006; 8:122-9. PubMed
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, J. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-14. PubMed
  • Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care 2006; 29:1711. PubMed
  • Mayer S, Cypess AM, Kocher ON, Berman SM, Huberman MS, Hartzband PI, Halmos B. Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol 2005; 23:1312-4. PubMed
  • Stram DO, Huberman M, Wu AH. Is residual confounding a reasonable explanation for the apparent protective effects of beta-carotene found in epidemiologic studies of lung cancer in smokers? Am J Epidemiol 2002; 155:622-8. PubMed
  • Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 2002; 89:604-11. PubMed
  • Petrovich Z, Lieskovsky G, Langholz B, Huberman M, Streeter O, Skinner DG. Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol 2002; 24:537-46. PubMed
  • Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr 2000; 24:977-80. PubMed
  • Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998; 82:2321-5. PubMed
  • Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996; 19:136-9. PubMed
  • Stuart K, Posner M, Campbell K, Huberman M. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol 1995; 18:300-2. PubMed
  • Eyre RC, Huberman MS, Balogh K. Non-Hodgkin's lymphoma of the kidney with inferior vena caval extension. Urol Int 1993; 51:43-5. PubMed
  • Huberman M, Bering H, Fallon B, Tessitore J, Sonnenborn H, Paul S, Zeffren J, Levitt D, Groopman J. A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors. Cancer 1991; 68:1708-13. PubMed
  • Steele G, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg 1991; 126:696-701; discussion 701-2. PubMed
  • Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549-51. PubMed
  • Bern MM, Wallach SR, Arkin CF, Lokich JJ, Huberman MS, Anderson NR, Corkery JC, Paul SD, Phillips DF, Sonneborn HA. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age. Cancer Treat Rep 1987; 71:201-3. PubMed
  • Huberman MS, Lokich JJ, Hill T, Kaldany A, Kassis A, Price T, Moore C, Davis S, Kasulis P, Monaco AP. Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study. Cancer Immunol Immunother 1985; 23:137-42. PubMed
  • Groopman JE, Sarngadharan MG, Salahuddin SZ, Buxbaum R, Huberman MS, Kinniburgh J, Sliski A, McLane MF, Essex M, Gallo RC. Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 102:63-6. PubMed
  • Matelski HW, Lokich JJ, Huberman MS, Zipoli TE, Paul S, Sonneborn H, Philips D. Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer. Am J Clin Oncol 1984; 7:729-32. PubMed
  • Huberman MS. Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol 1983; 10:238-48. PubMed
  • Levenson RM, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD. Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep 1981; 65:905-7. PubMed
  • Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93:223-30. PubMed
  • Huberman MS, Bunn PA, Matthews MJ, Ihde DC, Gazdar AF, Cohen MH, Minna JD. Hepatic involvement in the cutaneous T-cell lymphomas: results of percutaneous biopsy and peritoneoscopy. Cancer 1980; 45:1683-8. PubMed
Hide